The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued biotech stocks to buy right now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on April 7 that its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated. According to the collaboration, Vertex has licensed Halozyme Therapeutics’ (NASDAQ:HALO) Hypercon™ technology for use in up to three drug targets. Management stated that Hypercon™ is an innovative microparticle technology allowing for hyperconcentration of drugs and biologics, reducing injection volume for the same dosage and enabling convenient, at-home administration.

Helen Torley, President and Chief Executive Officer of Halozyme Therapeutics, Inc. (NASDAQ:HALO), stated that the collaboration highlights the potential and versatility of the company’s Hypercon technology to “enable small volume, patient-delivered next‑generation biologics”.

The terms of the exclusive agreement state that Vertex will make a $15 million upfront payment to Halozyme Therapeutics, Inc. (NASDAQ:HALO), along with potential future milestone payments. In addition, Halozyme Therapeutics, Inc. (NASDAQ:HALO) will be entitled to royalties on net sales of products developed using the Hypercon™ technology.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology. They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.

While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.